Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies

Eribulin mesylate has efficacy in patients who have received ≥2 prior chemotherapies for metastatic breast cancer (MBC) including an anthracycline and taxane. Phase 2 trials showed clinical activity and acceptable tolerability of first-line eribulin (HER2− MBC; Study 206) and eribulin plus trastuzum...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Shaughnessy, Joyce, McIntyre, Kristi, Schwartzberg, Lee, Wilks, Sharon, Puhalla, Shannon, Berrak, Erhan, Song, James, Vahdat, Linda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4577494/
https://www.ncbi.nlm.nih.gov/pubmed/26413438
http://dx.doi.org/10.1186/s40064-015-1322-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4577494/
https://www.ncbi.nlm.nih.gov/pubmed/26413438
http://dx.doi.org/10.1186/s40064-015-1322-y

Ejemplares similares